Christoffer Lambring, Kelly Varga, Keriman Livingston, Nicholas Lorusso, Amil Dudhia, Riyaz Basha
{"title":"姜黄素及其衍生物在结直肠癌中的治疗应用。","authors":"Christoffer Lambring, Kelly Varga, Keriman Livingston, Nicholas Lorusso, Amil Dudhia, Riyaz Basha","doi":"10.1615/OncoTherap.2022044575","DOIUrl":null,"url":null,"abstract":"<p><p>Curcumin (CUR), a natural phenolic compound, has been increasingly investigated in several malignancies due to its safe profile and ability to affect a wide range of oncogenic targets. With the ability to affect metastasis, apoptosis, and angiogenesis in colorectal cancer (CRC) and its tolerability at high doses, CUR is an attractive target for study. However, poor bioavailability and unfavorable pharmacokinetics and pharmacodynamics have hampered CUR's efficacy in clinical trials. Development of its derivatives and alternative delivery methods have shown the potential to overcome its inherent bioavailability issues. Recent analyses of various derivatives and nanoparticle encapsulation of CUR have demonstrated increased effectiveness in CRC studies. A major advantage of CUR has been its synergistic effects when used in combination with various chemotherapeutic agents. CUR offers a unique treatment option in terms of patient safety and its ability to be used in combination with current treatments for CRC. Further development of its derivatives and alternative delivery options offer potential new avenues of treatment that could outperform previous efforts to establish CUR as a CRC therapy.</p>","PeriodicalId":74340,"journal":{"name":"Onco therapeutics","volume":"9 1","pages":"51-62"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262216/pdf/nihms-1904401.pdf","citationCount":"0","resultStr":"{\"title\":\"Therapeutic Applications of Curcumin and Derivatives in Colorectal Cancer.\",\"authors\":\"Christoffer Lambring, Kelly Varga, Keriman Livingston, Nicholas Lorusso, Amil Dudhia, Riyaz Basha\",\"doi\":\"10.1615/OncoTherap.2022044575\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Curcumin (CUR), a natural phenolic compound, has been increasingly investigated in several malignancies due to its safe profile and ability to affect a wide range of oncogenic targets. With the ability to affect metastasis, apoptosis, and angiogenesis in colorectal cancer (CRC) and its tolerability at high doses, CUR is an attractive target for study. However, poor bioavailability and unfavorable pharmacokinetics and pharmacodynamics have hampered CUR's efficacy in clinical trials. Development of its derivatives and alternative delivery methods have shown the potential to overcome its inherent bioavailability issues. Recent analyses of various derivatives and nanoparticle encapsulation of CUR have demonstrated increased effectiveness in CRC studies. A major advantage of CUR has been its synergistic effects when used in combination with various chemotherapeutic agents. CUR offers a unique treatment option in terms of patient safety and its ability to be used in combination with current treatments for CRC. Further development of its derivatives and alternative delivery options offer potential new avenues of treatment that could outperform previous efforts to establish CUR as a CRC therapy.</p>\",\"PeriodicalId\":74340,\"journal\":{\"name\":\"Onco therapeutics\",\"volume\":\"9 1\",\"pages\":\"51-62\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262216/pdf/nihms-1904401.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Onco therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1615/OncoTherap.2022044575\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Onco therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1615/OncoTherap.2022044575","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
姜黄素(CUR)是一种天然酚类化合物,由于其安全的特性和影响多种致癌靶点的能力,在多种恶性肿瘤中的研究越来越多。姜黄素能够影响结直肠癌(CRC)的转移、凋亡和血管生成,而且在高剂量下具有耐受性,因此是一个极具吸引力的研究对象。然而,较差的生物利用度以及不利的药代动力学和药效学影响了 CUR 在临床试验中的疗效。其衍生物和替代给药方法的开发显示出克服其固有的生物利用度问题的潜力。最近对 CUR 的各种衍生物和纳米颗粒封装进行的分析表明,CUR 在 CRC 研究中的有效性有所提高。CUR 的一大优势是与各种化疗药物联合使用时的协同效应。就患者安全性及其与目前治疗 CRC 的药物联合使用的能力而言,CUR 提供了一种独特的治疗选择。进一步开发其衍生物和替代给药方案为治疗提供了潜在的新途径,可能会超越之前将 CUR 确立为 CRC 治疗方法的努力。
Therapeutic Applications of Curcumin and Derivatives in Colorectal Cancer.
Curcumin (CUR), a natural phenolic compound, has been increasingly investigated in several malignancies due to its safe profile and ability to affect a wide range of oncogenic targets. With the ability to affect metastasis, apoptosis, and angiogenesis in colorectal cancer (CRC) and its tolerability at high doses, CUR is an attractive target for study. However, poor bioavailability and unfavorable pharmacokinetics and pharmacodynamics have hampered CUR's efficacy in clinical trials. Development of its derivatives and alternative delivery methods have shown the potential to overcome its inherent bioavailability issues. Recent analyses of various derivatives and nanoparticle encapsulation of CUR have demonstrated increased effectiveness in CRC studies. A major advantage of CUR has been its synergistic effects when used in combination with various chemotherapeutic agents. CUR offers a unique treatment option in terms of patient safety and its ability to be used in combination with current treatments for CRC. Further development of its derivatives and alternative delivery options offer potential new avenues of treatment that could outperform previous efforts to establish CUR as a CRC therapy.